COVID-19 is a clinical syndrome ranging from mild symptoms to severe pneumonia that often leads to respiratory failure, need for mechanical ventilation, and death. Most of the lung damage is driven by a surge in inflammatory cytokines [interleukin-6, interferon-γ, and granulocyte-monocyte stimulating factor (GM-CSF)]. Blunting this hyperinflammation with immunomodulation may lead to clinical improvement. GM-CSF is produced by many cells, including macrophages and T-cells. GM-CSF-derived signals are involved in differentiation of macrophages, including alveolar macrophages (AMs). In animal models of respiratory infections, the intranasal administration of GM-CSF increased the proliferation of AMs and improved outcomes. Increased levels of GM-CSF have been recently described in patients with COVID-19 compared to healthy controls. While GM-CSF might be beneficial in some circumstances as an appropriate response, in this case the inflammatory response is maladaptive by virtue of being later and disproportionate. The inhibition of GM-CSF signaling may be beneficial in improving the hyperinflammation-related lung damage in the most severe cases of COVID-19. This blockade can be achieved through antagonism of the GM-CSF receptor or the direct binding of circulating GM-CSF. Initial findings from patients with COVID-19 treated with a single intravenous dose of mavrilimumab, a monoclonal antibody binding GM-CSF receptor α, showed oxygenation improvement and shorter hospitalization. Prospective, randomized, placebo-controlled trials are ongoing. Anti-GM-CSF monoclonal antibodies, TJ003234 and gimsilumab, will be tested in clinical trials in patients with COVID-19, while lenzilumab received FDA approval for compassionate use. These trials will help inform whether blunting the inflammatory signaling provided by the GM-CSF axis in COVID-19 is beneficial.
【저자키워드】 COVID-19, SARS-CoV-2, IL-6, GM-CSF, Cytokine release syndrome, mavrilimumab, 【초록키워드】 respiratory infections, Macrophage, clinical trial, Respiratory failure, Trial, macrophages, mechanical ventilation, Hospitalization, monoclonal antibody, T-cells, animal model, monoclonal antibodies, outcomes, Randomized, cells, hyperinflammation, Prospective, placebo-controlled trial, death, Clinical improvement, receptor, severe pneumonia, alveolar macrophage, intranasal, Inflammatory cytokine, compassionate use, binding, Signaling, Inflammatory response, administration, Oxygenation, lung damage, proliferation, interferon-γ, Mild symptom, syndrome, help, Severe case, FDA approval, healthy controls, circulating, blockade, while, MOST, inflammatory signaling, blunting, produced, tested, described, involved, provided, treated, driven by, Increased, intravenous dose, patients with COVID-19, 【제목키워드】 Strategy, rationale, targeting,